Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression - Scorecard - MDSpire
Advertisement
Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression
Clinical Scorecard: Clinical Case Analysis: Neoadjuvant Chemoimmunotherapy Results in Complete Pathological Response in Two Patients with Stage III EGFR-Mutant NSCLC Exhibiting High PD-L1 Levels
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Care Setting
Oncology, specifically for neoadjuvant treatment of EGFR-mutant NSCLC.
Key Highlights
adverse_effects
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
R
e
g
u
l
a
r
f
o
l
l
o
w
-
u
p
i
m
a
g
i
n
g
a
n
d
c
l
i
n
i
c
a
l
a
s
s
e
s
s
m
e
n
t
s
e
v
e
r
y
3
m
o
n
t
h
s
p
o
s
t
-
t
r
e
a
t
m
e
n
t
.
Risks
Patient & Prescribing Data
Patients with resectable locally advanced EGFR-mutant NSCLC and high PD-L1 expression.
Neoadjuvant chemoimmunotherapy may overcome immune tolerance in selected patients.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.
